Neumedicines plans to collaborate with strategic development partners to advance therapeutically important protein-based medicines.

At present, Neumedicines is focused on building its NMIL12-1 therapeutic pipeline to treat and support patients suffering from hematopoietic-depleting treatments in oncology and related conditions through partnerships and alliances in the U.S., Europe, and Japan.

For more information about business and corporate development opportunities, please direct inquiries to:

Lena Basile, Ph.D., J.D.
President, Chief Executive Officer
Tel: 818.606.2638
Fax: 626.844.3810
E-mail: basile@neumedicines.com